Merus completed its rollout of Phase 2 head and neck cancer data on Thursday, touting overall survival results that at least ...

Jazz's Zepzelca + Roche's Tecentriq shows 27% reduced death risk & improved survival in lung cancer trial; FDA application ...

Beam Therapeutics CEO John Evans warns against AI hype in drug development, drawing parallels to past CRISPR expectations, ...

The House of Representatives on Thursday passed President Donald Trump’s tax cut package, with steep Medicaid cuts, PBM ...

Hinge Health shares jumped 23% in its first day trading as a public company, setting the tone for digital health after a ...

FDA Commissioner Marty Makary defended thousands of staff cuts during his first congressional hearing since taking office, ...

Cigna on Wednesday said it negotiated with Novo Nordisk and Eli Lilly to secure deeper GLP-1 drug discounts for employers ...

The White House released its first MAHA Commission report, detailing some of the Trump administration’s top priorities for ...

First sale rule allows pharma companies to reduce tariff duties by declaring lower drug values at US customs, as industry ...

Sanofi will acquire Vigil for its oral small molecule TREM2 project, dubbed VG-3927, that is on tap for a Phase 2 in ...

Hinge Health prices IPO at $32/share, valuing company at $3B. CEO Daniel Perez's firm to trade as HNGE on NYSE, raising ...

The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee vot­ed 8-0 against a new in­di­ca­tion for Pfiz­er’s Talzen­na in ...